Church of PeptidesSearch
Portrait representing CJC-1295
Pilgrims · Not FDA-approved

CJC-1295

The Long Bell

An experimental long-acting growth-hormone-releasing hormone analog

CJC-1295 is an experimental long-acting growth-hormone-releasing hormone analog. Small human studies measured increases in growth hormone and IGF-1, rather than establishing benefits for recovery, athletic performance, or healthy aging.

Evidence ladder: Controlled human evidenceLimited controlled human pharmacologyIndividual component record
ClassificationPilgrims
Evidence summaryLimited controlled human pharmacology
OriginConjuChem · Montreal, Canada · human studies reported in the 2000s
Scientific record

What the evidence says

What is established

  • Small controlled studies demonstrated prolonged stimulation of growth hormone and IGF-1.
  • Those pharmacodynamic findings do not establish meaningful clinical benefit for wellness or athletic goals.

Side effects, risks and limits

  • FDA identifies limited clinical data, potential immunogenicity and peptide-impurity concerns.
  • FDA has identified serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction.
  • Long-term safety and clinical outcomes remain uncertain.
Doctide’s verdict

The Long Bell rings convincingly in hormone measurements. Doctide still asks what improved for the person: louder signaling alone cannot establish better recovery, safer aging, or a favorable balance of benefit and harm.

Documented history

Where the real story begins

Human research reported in 2006 investigated prolonged growth-hormone and IGF-1 responses to CJC-1295 in healthy adults. This was a pharmacology milestone: it showed that the hormonal signal could be extended, without establishing a broadly useful clinical treatment. Historical source.

ConjuChem · Montreal, Canada · human studies reported in the 2000s
Combination recordCJC-1295 + Ipamorelin →
Book of the Canon · Comic scripture

The laboratory legend

CJC-1295 rang one bell and waited days for the echo. Doctide measured the echo carefully and crossed out every benefit the experiment had not actually tested.

This bold passage is invented comedy, not scientific or historical fact.
Editorial recordProfile editorial revision: October 4, 2026Prepared under the Church of Peptides evidence standardEditorial review: Church of PeptidesIndependent clinical review: none to dateContent evidence reviewed: September 14, 2026
Evidence ledger

Sources

  1. Human pharmacology study · JCEM
  2. FDA compounding safety assessment
  3. CJC-1295 controlled human pharmacology, 2006

Fiction disclosure: The bold laboratory legend is invented. The historical and scientific sections are sourced summaries.

Educational entertainment only. Not medical advice, diagnosis, dosing guidance, or a recommendation to obtain or use a product.